AbbVie stock (US00287Y1091): Q1 earnings beat and guidance raise drive 3.1% gain

AbbVie shares climbed 3.1% to $207.98 on May 12, 2026, after reporting Q1 EPS of $2.65 beating estimates and raising full-year revenue guidance to $67.3 billion.

AbbVie shares rose 3.1% to $207.98 on May 12, 2026, on the NYSE after the pharmaceutical company reported first-quarter results that exceeded expectations, according to ad-hoc-news.de as of May 12, 2026. Earnings per share came in at $2.65, topping the consensus of $2.59, with revenue up 12% year-over-year and adjusted EPS growing 8%, per Morningstar as of May 13, 2026. Management lifted its full-year revenue outlook to $67.3 billion.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AbbVie Inc.
• Sector/industry: Pharmaceuticals / Biopharmaceuticals
• Headquarters/country: North Chicago, United States
• Core markets: United States, Europe, International
• Key revenue drivers: Immunology, Oncology, Neuroscience, Skyrizi, Rinvoq
• Home exchange/listing venue: NYSE (ABBV)
• Trading currency: USD

AbbVie: core business model

AbbVie develops and markets innovative therapies in immunology, oncology, neuroscience, eye care, and virology. The company focuses on blockbuster drugs addressing high unmet needs in chronic diseases. Its business model relies on a diversified portfolio transitioning from legacy products like Humira to newer growth drivers such as Skyrizi and Rinvoq. AbbVie invests heavily in R&D, with a pipeline emphasizing biologics and small molecules for US and global markets.

For US investors, AbbVie represents a key player in the biopharma sector, listed on the NYSE with substantial exposure to the world's largest pharmaceutical market. The company's therapies serve millions of patients, contributing to its stable revenue base amid patent cliffs.

Main revenue and product drivers for AbbVie

First-quarter 2026 revenue grew 12.4% year-over-year to approximately $15 billion, driven by strong sales of Skyrizi and Rinvoq offsetting Humira biosimilar erosion, according to DripInvesting as of May 2026. Skyrizi and Rinvoq are scaling rapidly in immunology, while neuroscience products add momentum. Humira, once the top seller, faces competition but newer assets ensure growth.

AbbVie maintains a quarterly dividend of $1.73, yielding around 3.4% at recent share prices of $204-$208. The company has raised dividends for over five decades, with a five-year growth rate above 6%, supporting its appeal for income-focused US investors.

Industry trends and competitive position

The biopharma industry faces biosimilar pressures and pricing scrutiny, but AbbVie differentiates through its immunology dominance and pipeline progress. Competitors like Eli Lilly and Pfizer trail in certain metrics; AbbVie's return on invested capital stands at 28.41% normalized, per Morningstar data as of May 2026. Skyrizi and Rinvoq position AbbVie for mid-teens growth in key segments.

Why AbbVie matters for US investors

As a NYSE-listed giant, AbbVie offers US investors direct access to immunology innovation amid a $600+ billion domestic pharma market. Its US-centric revenue, robust dividends, and growth trajectory align with portfolios seeking defensive healthcare exposure with upside from new drugs.

Conclusion

AbbVie's Q1 results highlight resilient growth with EPS beats, revenue expansion, and upbeat guidance signaling portfolio strength. While Humira declines pose challenges, Skyrizi and Rinvoq drive momentum, bolstered by steady dividends. US investors track these developments as AbbVie navigates biopharma dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.